A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
about
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsMultidisciplinary management of nonfunctional neuroendocrine tumor of the pancreasTargeting the mTOR signaling pathway in neuroendocrine tumorsA phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057KNew therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agentsLow dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumorsPancreatic neuroendocrine tumors: a review.Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
P2860
Q26740374-C2AB4100-E082-457F-9B3F-2FF9CB993683Q26752757-16A36B3E-8DC5-4AE8-BB95-780733B9D261Q26852089-60C6DA79-88AB-44A3-9DCF-DEE9873221CDQ30301096-92F57274-3340-4BC6-BA08-5EDA3BFAD191Q30364864-01EBC0B6-D35C-4EA3-9D72-CC8ECE69C539Q30884794-81C41550-8014-4929-A58B-1DD3175187FDQ35677887-AAB84137-2746-4D63-A7E6-2C0901E5A2FDQ36107481-1141CAD3-2D33-4F9D-9242-3CDC4F7CD8A9Q38372459-007A8708-9801-4F07-A1DE-6E441CBF33B1Q38400485-27643870-3CC8-48BB-9C82-A6591428D38FQ38527936-32EF67D1-E140-4AD1-BF1E-541211390125Q38835123-36E18EF6-E2F9-44E7-9A3E-B73C0C0AE8C0Q38842250-7E9335AE-4C75-4BE0-B96D-1475A66D7C2FQ41559421-9E6F8C08-AD82-48BC-9D21-15388E051A08Q42379480-0B957201-D327-4B39-B563-BFE801E6594BQ44425475-02A54FCC-70DA-40B1-B9BC-87597C1DC6B2Q48295398-2B9A8F57-F18C-4DEE-867E-FCF59D5B75A3Q51122180-AB1BB136-B800-4AC0-970F-2A611920AB94
P2860
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.
@ast
A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.
@en
type
label
A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.
@ast
A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.
@en
prefLabel
A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.
@ast
A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.
@en
P2093
P2860
P356
P1433
P1476
A prospective, phase 1/2 study ...... ncreatic neuroendocrine tumor.
@en
P2093
Andrew X Zhu
David P Ryan
Eileen Regan
Jennifer A Chan
Jill Allen
Keith Stuart
Lawrence Blaszkowsky
Marielle Gonzalez
Matthew H Kulke
P2860
P304
P356
10.1002/CNCR.28142
P407
P577
2013-06-03T00:00:00Z